Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria

Diabetologia

Volumn 39, Issue 12, 1996, Pages 1611-1616

  Schnack, Ch ^a   Hoffmann, W ^a   Hopmeier, P ^a   Schernthaner, G ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

ACE inhibitors; hypertension; microalbuminuria; nephropathy; NIDDM

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; RAMIPRIL;

ADULT; AGED; BLOOD PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATENOLOL; BLOOD PRESSURE; COHORT STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FELODIPINE; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL; VASODILATOR AGENTS;

EID: 0029857585     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050623     Document Type: Conference Paper

References (33)

1. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 310: 356-360
2. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G (1992) Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736-741
3. Schmitz A, Vaeth M (1988) Microalbuminuria: a major risk factor in non-insulin-dependent diabetes: a 10 year followup study of 503 patients. Diabet Med 5: 126-134
4. Kannel WB, Stampfer MJ, Castelli WP, Verter J (1984) The prognostic significance of proteinuria: the Framingham Study. A Heart J 108: 1347-1352
5. Parving HH, Hommel E (1990) Prognosis in diabetic nephropathy. BMJ 299: 230-233
6. Viberti GC, Yip-Messent J, Morocutti A (1992) Diabetic nephropalhy. Diabeles Care 15: 1216-1225
7. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A, Mathiesen ER (1991) Natural history of diabetic complications: early detection and progression (Symposium). Diabet Med 8: S33-S37
8. Hasslacher Ch, Wolfrum M, Stech G, Wahl P, Ritz E (1987) Diabetische Nephropathie bei Typ-II-Diabetes. Dtsch Med Wochenschr 112: 1445-1449
9. Nelson RG, Pettitt DJ, Baird HR, Charles MA, Liu QZ, Bennett PH, Knowler WC (1993) Prediabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellilus in Pima Indians. Diabelologia 36: 998-1001
10. Mogensen CE (1988) Management of diabetic renal involvemenl and disease. Lancet 1: 867-870
11. Parving HH, Smidt UM, Andersen AR, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175-1178
12. Zatz R, Dunn BR, Meyer TW, Anderson A, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930
13. Bakris GL, Barnhill BW, Sadler R (1992) Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 41: 912-919
14. Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 303: 210-216
15. Christiansen CK, Mogensen CE (1985) Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7: [Suppl 2]: 109-113
16. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen E, Svendsen PA (1987) Effects of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443-1447
17. Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud P (1991) Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 18: [Suppl 2]: S 165-S168
18. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581
19. Lewis EJ, Hunsigker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
20. Schnack C, Capek M, Banyai M, Kautzki-Willer A, Prager R, Schernthaner G (1994) Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in type 1 diabetic patients with microalbuminuria. Acta Diabetol 31: 14-18
21. Bretzel RG, Bollen CC, Maeser E, Federlin KF (1993) Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 21 [Suppl 3]: 53-64
22. Stornello M, Valvo EV, Scarpellato L (1989) Hemodynamic, renal and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type 2 diabetic patients with nephropathy. J Cardiovasc Pharmacol 14: 851-855
23. Bakris GL (1990) Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112: 707-708
24. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C, Kuenburg E, Schernthaner G (1991) Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 17: 15-21
25. McNally PG, Cooper ME (1994) Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus. Kluwer Academic publishers, pp 341-351
26. Elving LD, Wetzels JF, Van Lier HJ, De Nobel E, Berden JH (1994) Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 37: 604-609
27. Slataper R, Vicknair N, Sadler R, Bakris GL (1993) Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 153: 973-980
28. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1994) Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 43: 1108-1113
29. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R (1992) Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 105: 981-985
30. Chan JCN, Nicholls MG, Cheung CK, Law LK, Swaminathan R, Cockram CS (1995) Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Diabetes Care 18: 1001-1006
31. Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R (1994) Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. Clin Invest 72: 961-966
32. Nielson S, Schmitz A, Mogensen CE (1991) Rate of progression of nephropathy in normo- and microalbuminuric type 2 diabetic patients. Diabetologia 34 [Suppl 2]: A144 (Abstract)
33. Schnack C, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G (1994) Apolipoprotein (a) levels and atherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus. Nephron 66: 273-277